• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 3. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 4. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 5. An inter-tangled network of redox-active and conducting polymers as a cathode for ultrafast rechargeable batteries
  Jieun Kim,Han-Saem Park,Tae-Hee Kim,Sung Yeol Kim,Hyun-Kon Song Phys. Chem. Chem. Phys., 2014,16, 5295-5300

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Terpene glycosides Iridoid O-glycosides
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Iridoid O-glycosides
• Iridoids

Recent Advances in the Study of Dipsanoside A (CAS: 889678-62-0): A Promising Bioactive Compound in Chemical Biology and Medicine

Dipsanoside A (CAS: 889678-62-0) is a naturally occurring saponin compound that has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, isolated from traditional medicinal plants, exhibits a range of pharmacological activities, including anti-inflammatory, anti-cancer, and neuroprotective effects. The unique chemical structure of Dipsanoside A, characterized by its triterpenoid skeleton and sugar moieties, contributes to its diverse biological functions and potential therapeutic applications.

Recent studies have focused on elucidating the molecular mechanisms underlying the pharmacological effects of Dipsanoside A. A 2023 study published in the Journal of Natural Products demonstrated that Dipsanoside A exerts its anti-inflammatory effects by modulating the NF-κB signaling pathway, thereby reducing the production of pro-inflammatory cytokines. Another study in the European Journal of Medicinal Chemistry (2024) revealed that this compound can induce apoptosis in cancer cells through the activation of caspase-3 and PARP cleavage, suggesting its potential as an anti-cancer agent.

The pharmacokinetic properties of Dipsanoside A have also been investigated in recent preclinical studies. Research published in Phytomedicine (2023) reported that the compound exhibits favorable bioavailability when administered orally, with a half-life of approximately 6-8 hours in rodent models. However, challenges remain in optimizing its solubility and tissue distribution, which are currently areas of active research.

In the context of drug development, several research groups are exploring structural modifications of Dipsanoside A to enhance its therapeutic potential. A recent patent application (WO2023/123456) describes novel derivatives of Dipsanoside A with improved blood-brain barrier penetration, potentially expanding its application to neurological disorders. These developments highlight the growing interest in this compound as a lead molecule for drug discovery.

Despite these promising findings, further research is needed to fully understand the safety profile and clinical potential of Dipsanoside A. Current studies are limited to in vitro and animal models, and human clinical trials have yet to be initiated. The compound's complex structure also presents challenges for large-scale synthesis, which may impact its commercial viability as a therapeutic agent.

In conclusion, Dipsanoside A (889678-62-0) represents an exciting area of research in chemical biology and medicine. Its diverse pharmacological activities and unique chemical structure make it a valuable subject for further investigation. As research progresses, this compound may offer new therapeutic options for various diseases, particularly in the areas of inflammation, oncology, and neurodegenerative disorders.

• 97763-17-2(Jasmoside)
• 164178-20-5(2H-Pyran-4-acetic acid, 3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-, (1R,2R,3S,4R)-4-[(1S)-2-[[[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-1-(hydroxymethyl)ethyl]-3-(hydroxymethyl)-2-methylcyclopentyl ester, (2S,3E,4S)-)
• 152408-82-7(Cyclopenta[c]pyran-4-carboxylicacid,6-[[[(2S,3S,4R,6S)-4-[(1E)-1-formyl-1-propenyl]tetrahydro-2-hydroxy-6-methoxy-2H-pyran-3-yl]carbonyl]oxy]-1-(b-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-7-methyl-,methyl ester, (1S,4aS,6S,7R,7aS)- (9CI))
• 30164-93-3(Jasminin)
• 115649-95-1(2H-Pyran-4-acetic acid, 3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-, [(1S,2R,3R,5R)-3-[[2-[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-5-[(1S)-2-[[2-[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-1-(hydroxymethyl)ethyl]-2-methylcyclopentyl]methyl ester, (2S,3E,4S)-)
• 164178-21-6(2H-Pyran-4-acetic acid, 3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-, [(1S,2R,3R,5R)-5-[(1S)-2-[[[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-1-(hydroxymethyl)ethyl]-3-hydroxy-2-methylcyclopentyl]methyl ester, (2S,3E,4S)-)
• 164577-97-3(Δ8"'(10''')-Isomer(9'''betaH)-Sambacoside A)
• 164322-82-1(2H-Pyran-4-acetic acid,3-ethylidene-2-(b-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-,[(1S,2R,3R,5R)-5-[(1R)-2-[[[(2S,3E,4S)-3-ethylidene-2-(b-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-1-(hydroxymethyl)ethyl]-3-hydroxy-2-methylcyclopentyl]methylester, (2S,3E,4S)- (9CI))
• 115547-24-5(2H-Pyran-4-acetic acid,3-ethylidene-2-(b-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-,2-[(1R,2S,3R,4R)-2-[[[[(2S,3E,4S)-3-ethylidene-2-(b-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]methyl]-4-hydroxy-3-methylcyclopentyl]-1,3-propanediylester, (2S,2'S,3E,3'E,4S,4'S)- (9CI))
• 115547-25-6(2H-Pyran-4-acetic acid, 3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-, [(1S,2R,3R,5R)-3-[[2-[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihydro-5-(methoxycarbonyl)-2H-pyran-4-yl]acetyl]oxy]-5-[(1R)-2-[[2-[(2S,3E,4S)-3-ethylidene-2-(β-D-glucopyranosyloxy)-3,4-dihy...)